Introduction {#sec1}
============

Cholecystectomy is the standard treatment for acute cholecystitis once conservative treatment has proven ineffective. Unfortunately not all patients are suitable for this procedure. The most common contraindications for cholecystectomy are: old age, severe comorbidities, especially cancer, and previous abdominal surgery \[[@cit0001]--[@cit0003]\]. In patients with advanced cancer located in the area of the hepatic hilum or pancreas, or patients who have undergone previous surgery in this area, cholecystectomy may turn out to be much more difficult to perform and may be associated with more complications than the standard procedure. In those patients (especially when they are in poor overall condition) there is a need for a different, less invasive mode of therapy. Until now the only alternative for cholecystectomy in such cases (besides conservative treatment) has been percutaneous transhepatic gallbladder drainage (PTGBD) \[[@cit0004]--[@cit0006]\]. However, PTGBD involves a risk of multiple complications, including biliary peritonitis, bleeding, catheter migration, dislodgement, or obstruction, pneumothorax, and bile leak \[[@cit0007]--[@cit0009]\]. Practical difficulties associated with the percutaneous catheter are also a considerable disadvantage of PTGBD, as the catheter has to be checked for dislocation or obstruction, and the patient needs to remain in a forced position while resting, and may experience pain. Percutaneous drainage also results in dehydration and electrolyte imbalance. Moreover, it may be difficult to decide on the right time to discontinue treatment. Additionally, PTGBD may be difficult or contraindicated in patients with ascites, coagulopathy, or dementia \[[@cit0010], [@cit0011]\]. These factors necessitate a search for new treatments in patients unfit for cholecystectomy. Recently, endoscopic ultrasound-guided gallbladder drainage (EUSGBD) has been gaining popularity \[[@cit0012]--[@cit0014]\]. The EUSGBD method consists in stent placement so as to create a permanent fistula connecting the gallbladder to the stomach or the duodenal bulb, thus enabling drainage of its contents to the gastrointestinal tract. Biliary drainage to the gastrointestinal tract, rather than percutaneously to the outside of the body, enhances patient comfort due to the lack of a percutaneous catheter. Bile is drained from the gallbladder in a more physiological manner, preventing the loss of all its components secreted by the liver. The EUSGBD is still a new procedure, and the discussion regarding the proper technique and equipment is still ongoing, involving such issues as the location of the fistula, the type of stents to be used and the appropriate time for stent removal. There is also the question about the possibility of using EUSGBD as an alternative to cholecystectomy in cases of cholecystitis and cholelithiasis. Beside the treatment of cholecystitis, other applications for EUSGBD also exist \[[@cit0015]\]. The method may be used for treatment of obstructive jaundice due to common bile duct (CBD) obstruction, when currently used methods such as bile duct dilation or stenting (endoscopic or percutaneous), or endoscopic ultrasound-guided biliary drainage, cannot be used or have proven ineffective. The formed fistula can also be used for performing cholecystoscopy with the removal of concretions or polyps.

Aim {#sec2}
===

The purpose of the paper was to present our early experience with EUS-guided gallbladder drainage in the treatment of cholecystitis in patients who are not suitable for cholecystectomy.

Material and methods {#sec3}
====================

The procedure was performed in 5 patients (1 female) aged 27--81 years (mean age: 67 years) with acute cholecystitis. Two of the patients also had symptoms of jaundice due to obstruction of the CBD in the course of pancreatic head cancer. In 4 patients, cholecystectomy was contraindicated due to advanced cancer, and in one, cardiovascular and neurological contraindications existed. The procedures were performed under general anesthesia. A 14.6 mm single channel ultrasound endoscope with a 3.7 mm inner diameter (Olympus, Tokyo, Japan) was inserted into the duodenum, to identify the gallbladder and locate it relative to the gastrointestinal wall. Anatomy may differ between patients -- in some, a larger portion of the gallbladder wall may be adjacent to the pyloric part of the stomach or to the duodenal bulb than in others. Given these differences, we performed a cholecystogastric anastomosis in 2 cases, and a cholecystoduodenal anastomosis in the 3 remaining ones. After determining the fistula location, the gallbladder was punctured with a 19-gauge needle introduced through the endoscope channel ([Photo 1](#f0001){ref-type="fig"}), and bile aspiration was performed to verify the correct identification of the gallbladder. When selecting the puncture location, we also assessed the locations of major blood vessels using Doppler imaging. A 0.035 inch guidewire (Boston Scientific Dreamwire) was advanced through the needle inserted in the gastric or duodenal wall. The guidewire was coiled to prevent dislodgement at subsequent stages of the procedure. The needle was withdrawn, and an 8.5 Fr cystotome (Cook Medical, Bloomington, Indiana) was introduced over the guidewire. The fistula between the gastric or duodenal wall and the gallbladder wall was enlarged by electrocoagulation. Once the fistula had been formed, the cystotome was withdrawn, and a fully covered self-expandable metallic stent (SEMS) 4 cm in length and 1 cm in diameter was advanced over the guidewire using a special delivery system (Boston Scientific WallFlex). The delivery system consists of an exterior tube, metal stent and a delivery catheter. After the exterior tube was removed, the stent fully expanded, creating the anastomosis. Next the delivery catheter was removed along with the guidewire. To avoid bile leakage, we decided against gallbladder lavage. Additionally, a 4 cm 8.5 Fr double pigtail stent was placed in the SEMS lumen to secure the anastomosis and prevent SEMS migration ([Photo 2](#f0002){ref-type="fig"}). The mean operation time was 33 min. In one patient, the SEMS was removed 30 days after the procedure, while in the remaining patients, the SEMS were not removed.

![Gallbladder puncture with a 19-gauge needle](WIITM-14-34105-g001){#f0001}

![Double pigtail stent placed in the SEMS lumen to prevent SEMS migration](WIITM-14-34105-g002){#f0002}

Results {#sec4}
=======

All the procedures were performed with no perioperative complications. In all patients, the clinical symptoms of cholecystitis subsided within 3--15 days (mean: 8.6 days). During this time, signs of inflammation, such as increased C-reactive protein (CRP) levels, increased white blood cells count (WBC), and fever, decreased considerably ([Table I](#t0001){ref-type="table"}). In the 2 patients showing symptoms of CBD obstruction in addition to cholecystitis, these symptoms subsided within 3--6 days following the surgery (mean: 4.5 days), and a significant decrease of bilirubin levels was observed ([Table I](#t0001){ref-type="table"}). Four weeks after the procedure, the patients were admitted for a 1-day follow-up hospitalization, including a physical examination, ultrasound examination, gastroscopy, and laboratory tests (4 patients were followed up, as 1 patient died due to cancer progression). Cholecystitis did not recur in any of the 4 patients. The patients reported no pain, either fasting or postprandial, and had no fever. In 3 patients, laboratory inflammation markers were normal; 1 patient had an increased CRP level ([Table I](#t0001){ref-type="table"}). In 3 patients, gastroscopy showed unobstructed, functional anastomoses; therefore, both the SEMS and the pigtail stents were left in place to continue drainage. In 1 of these patients, the fistula was used to remove a gallbladder polyp. In the other 2 of these patients, the examination showed biliary concretions, which were also removed through the fistula. In the remaining patient, the follow-up showed that the SEMS had migrated to the gallbladder lumen, and the cholecystoduodenal fistula had been obliterated. The SEMS migration into the gallbladder was also confirmed by abdominal ultrasound examination. The pig-tail stent could not be located -- it had likely moved to the lumen of the gastrointestinal tract, loosening the SEMS and enabling its migration. We continued monitoring the patient's condition, and another evaluation for cholecystectomy was performed after 3 months, but the procedure was not performed due to cardiovascular contraindications. During subsequent follow-ups, at 6 and 12 months, the patient had no symptoms of cholecystitis or any other complaints, despite the SEMS in the gallbladder lumen.

###### 

Surgical treatment outcomes

  Parameter                                                                 Patient   Mean                                  
  ------------------------------------------------------------------------- --------- ------ ----- ------ ----------------- -------
  Age \[years\]                                                             73        81     27    75     80                67
  Diagnosis (a -- acute cholecystitis, b -- common bile duct obstruction)   a         a, b   a     a, b   a                 --
  Comorbidities (a -- pancreatic head cancer, b -- cholelithiasis)          a         a      a     a      b                 --
  Anastomosis location (a -- stomach, b -- duodenal bulb)                   a         b      a     b      b                 
  Time of hospitalization in days                                           10        6      9     3      15                8.6
  Parameters before the procedure:                                                                                          
   CRP \[mg/dl\]                                                            80        152    333   61     314               188
   Serum WBC \[10^3^/μl\]                                                   16        11     13    10     16                13.2
   Bilirubin \[mg/dl\]                                                      --        8      --    20     --                14
   Fever                                                                    Yes       Yes    Yes   No     Yes               --
   Complications                                                            No        No     No    No     No                --
  Parameters at discharge:                                                                                                  
   CRP \[mg/dl\]                                                            20        40     22    42     73                39.4
   Serum WBC \[10^3^/μl\]                                                   8         10     8     6      8                 8
   Bilirubin \[mg/dl\]                                                      --        3      --    4      --                3.5
   Fever                                                                    No        No     No    No     No                --
   Complications                                                            No        No     No    No     No                --
  Parameters 4 weeks after discharge[^1^](#tf1-1){ref-type="table-fn"}:                                                     
   CRP \[mg/dl\]                                                            2         --     4     30     4                 10
   Serum WBC \[10^3^/μl\]                                                   6         --     10    6      6                 7
   Bilirubin \[mg/dl\]                                                      0.4       --     0.4   2.5    0.6               0.975
   Fever                                                                    No        --     No    No     No                --
   Complications                                                            No        --     No    No     Stent migration   --

Patient II died from cancer progression.

Discussion {#sec5}
==========

Cholecystectomy is a common, relatively safe procedure, with a low complication rate, and clearly defined, commonly accepted indications. In some situations, however, the patient's condition does not allow for the procedure to be performed. Patients with cholecystitis in whom conservative treatment has not been effective and who are not suitable for cholecystectomy may be treated with PTGBD. This method, however, has multiple disadvantages, and the use of EUSGBD in lieu of PTGBD is considered increasingly often. Despite numerous references in the literature EUSGBD is still performed rather seldom in Poland. This may change due to the increasing access to endoscopic procedures. One might ask whether EUSGBD can be regarded as a less invasive procedure compared to laparoscopic cholecystectomy, since EUSGBD is also performed under general anesthesia. The EUSGBD is a significantly shorter procedure (mean operation time: 33 min), especially when compared with laparoscopic cholecystectomy performed in patients with tumors located in the hepatic hilum or the head of the pancreas. In such cases one may expect serious difficulties and a high probability of converting to laparotomy. This may lengthen the procedure several times. Additionally, EUSGBD does not require creation of pneumoperitoneum, and does not result in postoperative wounds, which helps to avoid numerous complications. A number of publications compare EUSGBD and PTGBD \[[@cit0014]\]. Tyberg *et al.* report that the two methods do not significantly differ in terms of technical and clinical success or complication rate, but that EUSGBD is associated with a lower percentage of re-intervention \[[@cit0016]\]. Irani *et al.* found similar rates of technical and clinical success for both procedures, but indicated that patients treated with EUSGBD required shorter hospitalization, reported less pain, required fewer re-interventions, and had a slightly lower complication rate \[[@cit0017]\]. Ahmed *et al.* performed a meta-analysis of 5 studies comparing PTGBD against EUSGBD, reporting similar rates of technical and clinical success, as well as similar mortality associated with both procedures, but concluding that EUSGBD was superior due to fewer complications, less pain, and shorter hospitalization. Furthermore, EUSGBD patients had lower rates of acute cholecystitis recurrence and rehospitalization, though these differences were not statistically significant \[[@cit0018]\]. These reports suggest that EUSGBD may soon replace PTGBD as a cholecystitis treatment method for patients unsuitable for cholecystectomy who have not been successfully treated conservatively. One may also wonder if EUSGBD could become a fully recognized form of relatively non-invasive treatment for acute cholecystitis. Yeung *et al*. suggest that in the future EUSGBD might in fact become the standard treatment for gallstones \[[@cit0019]\].

In cases of bile duct obstruction, the treatment of choice is bile duct stenting via endoscopic retrograde cholangiopancreatography (ERCP). If the ampulla of Vater or the bile duct cannot be accessed, percutaneous transhepatic biliary drainage (PTBD) is performed, but currently, endoscopic ultrasound-guided biliary drainage (EUSBD) is also used in a number of centers \[[@cit0020]--[@cit0022]\]. As demonstrated by Imai *et al.*, in cases where bile duct stenting via ERCP is not possible due to lack of access, while EUSBD would be difficult due to factors such as duodenal stenosis, bile duct wall thickening, interposing blood vessels, or non-dilated intrahepatic bile ducts, the use of EUSGBD instead of PTBD may be considered (as the patient might want to avoid having a percutaneous catheter placed), provided that the cystic duct is unobstructed \[[@cit0023]\].

In the present study, in the case of 2 patients in whom symptoms of CBD obstruction (high bilirubin, bile duct dilatation) were found beside cholecystitis, gallbladder drainage also proved effective in draining the bile ducts. Though attempts to treat CBD obstruction with EUSGBD are only warranted if stenting via ERCP or EUSBD cannot be performed, EUSGBD might turn out to be the preferred treatment in cases where the obstruction co-occurs with cholecystitis and cholecystectomy is contraindicated. Ogura *et al.* report having successfully treated a patient with acute cholecystitis and CBD obstruction caused by an advanced cancer of the bile duct, using endoscopic ultrasound-guided hepaticogastrostomy (a variant of EUSBD) and EUSGBD \[[@cit0024]\]. First, hepaticogastrostomy was performed to treat the obstruction, and cholecystitis was subsequently treated with PTGBD. As cholecystitis recurred, the team decided to perform EUSGBD. Based on our experience, in a case of CBD obstruction, performing EUSGBD first could help avoid both PTGBD and EUSHG. Therefore, in some specific cases, EUSGBD might prove to be a comprehensive treatment for acute cholecystitis with concurrent bile duct obstruction in patients unsuitable for cholecystectomy.

Another potential benefit of EUSGBD is also worth attention. As reported by Chan *et al.*, the fistula created during the procedure may be used for performing cholecystoscopy, offering further diagnostic and treatment options for gallbladder diseases (e.g. performing mucosal biopsies or visualizing and removing polyps) \[[@cit0025]\]. In the present study, the fistula was used to perform polypectomy in 1 patient, and to remove biliary concretions in 2 other patients.

One significant issue in the context of EUSGBD is stent selection. Initially, plastic double pigtail stents were used, though due to their small diameter and small lateral openings, drainage was limited to the liquid gallbladder contents. The use of these stents has nearly ceased, and most centers use either self-expanding metal stents \[[@cit0026]\] or lumen-apposing metal stents (LAMS) \[[@cit0027], [@cit0028]\]. The LAMS have been specifically designed for establishing fistulae between organs \[[@cit0029]\]. Due to their flanged shape, the stents are capable of fixing two non-adjoining organs in a position enabling the formation of a permanent anastomosis \[[@cit0030]\]. Thus, the use of LAMS is associated with fewer cases of stent migration or bile leak \[[@cit0031]\]. This warrants the prediction that LAMS may soon replace SEMS. In terms of stent placement, the innovative single-step technique reduces the number of endoscopic instrument changes required to perform the procedure, resulting in shorter procedure times and lower risk of error \[[@cit0032], [@cit0033]\]. When performing the procedures described here, we only had access to SEMS. The LAMS cost several times more than SEMS, which means that SEMS may still be used for economic reasons. A follow-up study by Choi *et al.* indicates that the use of SEMS produces very good long-term results \[[@cit0034]\]. The risk of SEMS migration may be curbed, as suggested by Takagi *et al.* \[[@cit0035]\], by additionally placing a pigtail stent in the lumen of the SEMS, which we did in all the described cases.

Another consideration, though maybe less significant, is the selection of the method for dilating the initial puncture to form a fistula. The available options include the use of a biliary dilation catheter, a balloon dilator, or a cystotome \[[@cit0023]\]. In our case, the use of a cystotome proved to be an effective solution for dilating the opening efficiently and without bleeding. More significant considerations include decisions about stent removal or fistula closure. Kamata *et al.*, who used SEMS, suggest removing the stents approximately 4 weeks after the surgery, to eliminate the risk of stent migration into the gallbladder or of stent obstruction by food particles, which might lead to cholecystitis recurrence \[[@cit0026]\]. The authors indicate that in order to avoid cholecystitis recurrence after SEMS removal, placement of a pigtail stent should be considered. Stent migration into the lumen of the gastrointestinal tract, and its subsequent natural elimination through this route, would not constitute a significant risk for the patient. If, however, the stent migrates into the gallbladder (as was the case in one of the present patients), it could cause a variety of unpredictable complications. Leaving the stent and the open fistula in place might result in cholecystitis recurrence, contributed to by gastric or intestinal content reflux into the lumen of the gallbladder. Walter *et al*., who used LAMS, left the stents in place for 3 months \[[@cit0036]\]. The authors report that when stents are left in place for that long, tissue overgrowth may occur, interfering with subsequent stent removal, and therefore, leaving the stent permanently should be considered, as this course of action prevents complications and patient discomfort associated with reoperation. A similar view is offered by Choi *et al.*, who reported that no serious complications occurred even when stents remained in place for 3 years \[[@cit0034]\]. Bearing in mind these recommendations, as well as the fact that 4 out of 5 of our patients had pancreatic cancer, and therefore had a short life expectancy, we decided against stent removal. This is also recommended by Chan and Teoh in patients with a short life expectancy \[[@cit0012]\].

Another problem is the selection of a location for the fistula, which may be formed between the gallbladder and the stomach, or between the gallbladder and the duodenal bulb. Walter *et al.* suggest that a more stable anastomosis is possible in the duodenum, due to the better and more stable fixation of the organ itself. The gastric wall can move relative to the adjacent organs, and peristalsis is stronger within the stomach \[[@cit0036]\]. A gastric anastomosis may also allow food particles to enter the gallbladder.

Takagi *et al.*, who used SEMS, state that a gastric anastomosis is technically easier, but is associated with a higher risk of bile leakage and stent migration, while a duodenal anastomosis is more difficult to perform, but produces better outcomes \[[@cit0035]\]. Considerations related to the fistula location also include the location of gallbladder puncture. Takagi *et al.* state that in the case of duodenal access, the neck of the gallbladder should be punctured (as it is less mobile), which prevents stent migration \[[@cit0035]\]. We attempted to perform a duodenal anastomosis whenever possible, but in 2 out of 5 cases, we performed a gastric anastomosis, as the distance between the gallbladder wall and the duodenal wall was too large, which excluded safe placement of a SEMS.

Since the present study was a retrospective one, and EUSGBD was chosen as the most suitable modality in the given clinical situations, approval from a bioethics committee was not sought.

Conclusions {#sec6}
===========

The EUSGBD seems to be a feasible, effective and safe treatment for acute cholecystitis in patients not suitable for cholecystectomy, who could not be successfully treated conservatively. Several ways of performing the procedure exist, and their relative effectiveness has not yet been sufficiently examined. Further studies are warranted to determine indications for this method, its efficacy and the optimal method for establishing such drainage. In the future, it is likely that EUSGBD will not only replace PTGBD, but may also become a fully recognized method for the treatment of gallbladder diseases in specific clinical situations. The EUSGBD may also be used to help patients with CBD obstruction in cases where other treatments are not possible. The method is particularly promising in cases of concurrent acute cholecystitis and CBD obstruction.
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